Teva, CureTech ally in cancer; agreement later terminated
Teva Pharmaceuticals has made a $6mm up-front equity investment in Israeli biotech CureTech (peptide cancer therapeutics), which will use the funds to develop its CT011 antibody in cancer applications.
- Includes Equity
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.